Trump Nominates White House Aide Overton to Lead FDA

President Donald Trump’s selection of White House Domestic Policy Council Deputy Director Heidi Overton as FDA commissioner places the agency’s oversight of drugs, vaccines, tobacco and food under new leadership at a time when staffing shortages and policy disputes have already disrupted operations. Trump announced the nomination on Truth Social, describing Overton as a “ROCKSTAR” who tackles difficult issues and will keep the United States at the forefront of scientific discovery. If confirmed, she would replace acting commissioner Kyle Diamantas, who stepped in after Marty Makary resigned in May amid reported disagreements over the authorization of fruit-flavored electronic cigarettes.

Overton’s recent visibility includes her appearance at an August 10 executive order signing that reevaluates childhood vaccine schedules. Department of Health and Human Services Secretary Robert F. Kennedy Jr. endorsed her, citing her judgment and commitment to results. House Speaker Mike Johnson praised her as a physician of deep faith aligned with an America First agenda. Senator Bill Cassidy, Republican of Louisiana and chairman of the Senate Health, Education, Labor and Pensions Committee, expressed reservations about her managerial experience at an agency facing morale problems and questioned her role in the vaccine order, calling that involvement “almost disqualifying.” Democrats, including Senator Patty Murray of Washington, described her as an anti-abortion extremist and pledged opposition, while reproductive health groups highlighted her past statements celebrating the overturning of Roe v. Wade and her work at the America First Policy Institute.

Confirmation requires navigating a 53-seat Republican majority, where three defections on the floor could block the nominee. Cassidy’s committee role gives him early influence over hearings. Overton’s prior positions on medication abortion access and agency priorities remain central points of contention raised by critics but have not been addressed in detail by the administration beyond general statements of support.